Lucid announces publication on EsoGuard in peer-reviewed journal Medicina

Lucid Diagnostics (LUCD) and subsidiary of PAVmed (PAVM), announced that the manuscript for its CLinical Utility of EsoGuard, or CLUE, study has been accepted for publication in the peer-reviewed journal Medicina. This is the fourth peer-reviewed publication presenting outstanding clinical utility data for the EsoGuard Esophageal DNA Test. In addition to demonstrating near-perfect provider decision impact, consistent with previous EsoGuard clinical utility studies, the study documented an exceptionally high 85% patient compliance with referral to confirmatory upper endoscopy, or EGD, following EsoGuard esophageal precancer testing in a real-world clinical setting. The full manuscript, entitled Real-world Clinical Utility of a Methylated DNA Biomarker Assay on Samples Collected with a Swallowable Capsule-balloon for Detection of Barrett’s Esophagus, or BE, is expected to be available in an upcoming online edition of Medicina, and follows the CLUE interim data report which was previously published in the Archives of Clinical and Biomedical Research in December of 2023. The prospective, multicenter CLUE study enrolled patients who met gastroenterology society guideline criteria for esophageal precancer screening from eight clinical centers. A total of 502 patients contributed to the clinical utility endpoints. The study demonstrated strong provider decision impact-100% of EsoGuard-positive patients were referred for confirmatory EGD, while over 99% of EsoGuard-negative patients were not referred. Among patients with positive EsoGuard results, compliance with follow-up EGD was 85%, more than double the patient compliance rate with screening EGD referral in the published literature.